Comprehensive Stock Comparison
Compare Puma Biotechnology, Inc. (PBYI) vs Revolution Medicines, Inc. (RVMD) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | PBYI | Beta 0.54 vs RVMD's 0.99 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | RVMD | +150.4% vs PBYI's +59.2% |
| Efficiency (ROA) | PBYI | 14.4% ROA vs RVMD's -48.0%, ROIC 24.7% vs -54.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing targeted cancer therapies, primarily for HER2-positive breast cancer. It generates revenue through sales of its FDA-approved drug neratinib (marketed as NERLYNX) and licensing agreements with pharmaceutical partners worldwide. The company's moat lies in its specialized expertise in HER2-targeted oncology and its patent-protected neratinib franchise, which addresses a specific niche in breast cancer treatment.
Revolution Medicines is a clinical-stage biotechnology company developing precision oncology therapies targeting RAS-addicted cancers. It generates revenue primarily through research collaborations and milestone payments — notably from its partnership with Sanofi on SHP2 inhibitors — while advancing its pipeline toward potential future drug sales. The company's competitive advantage lies in its deep expertise in RAS biology and its portfolio of novel inhibitors targeting multiple RAS pathway vulnerabilities that have historically been difficult to drug.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
PBYI leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). RVMD leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
PBYI and RVMD operate at a comparable scale, with $228M and $0 in trailing revenue.
| Metric | PBYIPuma Biotechnolog… | RVMDRevolution Medici… |
|---|---|---|
| RevenueTrailing 12 months | $228M | $0 |
| EBITDAEarnings before interest/tax | $46M | -$1.2B |
| Net IncomeAfter-tax profit | $31M | -$1.1B |
| Free Cash FlowCash after capex | $48M | -$914M |
| Gross MarginGross profit ÷ Revenue | +74.5% | — |
| Operating MarginEBIT ÷ Revenue | +16.3% | — |
| Net MarginNet income ÷ Revenue | +13.6% | — |
| FCF MarginFCF ÷ Revenue | +21.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +27.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -33.3% | -68.1% |
Valuation Metrics
| Metric | PBYIPuma Biotechnolog… | RVMDRevolution Medici… |
|---|---|---|
| Market CapShares × price | $287M | $20.1B |
| Enterprise ValueMkt cap + debt − cash | $286M | $19.9B |
| Trailing P/EPrice ÷ TTM EPS | 9.34x | -17.15x |
| Forward P/EPrice ÷ next-FY EPS est. | 22.80x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 7.67x | — |
| Price / SalesMarket cap ÷ Revenue | 1.26x | — |
| Price / BookPrice ÷ Book value/share | 2.22x | 11.89x |
| Price / FCFMarket cap ÷ FCF | 6.89x | — |
Profitability & Efficiency
PBYI delivers a 23.8% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-69 for RVMD. RVMD carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to PBYI's 0.22x. On the Piotroski fundamental quality scale (0–9), PBYI scores 7/9 vs RVMD's 1/9, reflecting strong financial health.
| Metric | PBYIPuma Biotechnolog… | RVMDRevolution Medici… |
|---|---|---|
| ROE (TTM)Return on equity | +23.8% | -69.3% |
| ROA (TTM)Return on assets | +14.4% | -48.0% |
| ROICReturn on invested capital | +24.7% | -54.3% |
| ROCEReturn on capital employed | +29.6% | -53.0% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 1 |
| Debt / EquityFinancial leverage | 0.22x | 0.10x |
| Net DebtTotal debt minus cash | -$1M | -$225M |
| Cash & Equiv.Liquid assets | $30M | $384M |
| Total DebtShort + long-term debt | $29M | $159M |
| Interest CoverageEBIT ÷ Interest expense | 5.49x | -49.69x |
Total Returns (with DRIP)
A $10,000 investment in RVMD five years ago would be worth $22,183 today (with dividends reinvested), compared to $5,583 for PBYI. Over the past 12 months, RVMD leads with a +150.4% total return vs PBYI's +59.2%. The 3-year compound annual growth rate (CAGR) favors RVMD at 56.2% vs PBYI's 13.9% — a key indicator of consistent wealth creation.
| Metric | PBYIPuma Biotechnolog… | RVMDRevolution Medici… |
|---|---|---|
| YTD ReturnYear-to-date | -1.2% | +29.1% |
| 1-Year ReturnPast 12 months | +59.2% | +150.4% |
| 3-Year ReturnCumulative with dividends | +47.7% | +281.2% |
| 5-Year ReturnCumulative with dividends | -44.2% | +121.8% |
| 10-Year ReturnCumulative with dividends | -87.3% | +253.0% |
| CAGR (3Y)Annualised 3-year return | +13.9% | +56.2% |
Risk & Volatility
PBYI is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than RVMD's 0.99 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RVMD currently trades 82.0% from its 52-week high vs PBYI's 74.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PBYIPuma Biotechnolog… | RVMDRevolution Medici… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.54x | 0.99x |
| 52-Week HighHighest price in past year | $7.68 | $124.49 |
| 52-Week LowLowest price in past year | $2.58 | $29.17 |
| % of 52W HighCurrent price vs 52-week peak | +74.2% | +82.0% |
| RSI (14)Momentum oscillator 0–100 | 69.9 | 54.1 |
| Avg Volume (50D)Average daily shares traded | 343K | 3.2M |
Analyst Outlook
Wall Street rates PBYI as "Buy" and RVMD as "Buy".
| Metric | PBYIPuma Biotechnolog… | RVMDRevolution Medici… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $122.25 |
| # AnalystsCovering analysts | 19 | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Puma Biotechnology,… (PBYI) | 100 | 63.8 | -36.2% |
| Revolution Medicine… (RVMD) | 100 | 295.86 | +195.9% |
Revolution Medicine… (RVMD) returned +122% over 5 years vs Puma Biotechnology,… (PBYI)'s -44%. A $10,000 investment in RVMD 5 years ago would be worth $22,183 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Puma Biotechnology,… (PBYI) | $0.00 | $228M | — |
| Revolution Medicine… (RVMD) | $0.00 | $0.00 | — |
Puma Biotechnology, Inc.'s revenue grew from $0M (2016) to $228M (2025) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Puma Biotechnology,… (PBYI) | -10.5% | 13.6% | +229.2% |
| Revolution Medicine… (RVMD) | -2.1% | -37.7% | -1718.4% |
Puma Biotechnology, Inc.'s net margin went from -11% (2017) to 14% (2025).
Chart 4P/E Ratio History — 4 Years
| Stock | 2022 | 2025 | Change |
|---|---|---|---|
| Puma Biotechnology,… (PBYI) | 208.4 | 9.8 | -95.3% |
Puma Biotechnology, Inc. has traded in a 5x–208x P/E range over 4 years; current trailing P/E is ~9x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Puma Biotechnology,… (PBYI) | -8.29 | 0.61 | +107.4% |
| Revolution Medicine… (RVMD) | -0.85 | -5.95 | -600.0% |
Puma Biotechnology, Inc.'s EPS grew from $-8.29 (2016) to $0.61 (2025).
Chart 6Free Cash Flow — 5 Years
Puma Biotechnology, Inc. generated $42M FCF in 2025 (+102% vs 2021). Revolution Medicines, Inc. generated $-914M FCF in 2025 (-494% vs 2021).
PBYI vs RVMD: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is PBYI or RVMD a better buy right now?
Puma Biotechnology, Inc. (PBYI) offers the better valuation at 9.3x trailing P/E (22.8x forward), making it the more compelling value choice. Analysts rate Puma Biotechnology, Inc. (PBYI) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PBYI or RVMD?
Over the past 5 years, Revolution Medicines, Inc. (RVMD) delivered a total return of +121.8%, compared to -44.2% for Puma Biotechnology, Inc. (PBYI). A $10,000 investment in RVMD five years ago would be worth approximately $22K today (assuming dividends reinvested). Over 10 years, the gap is even starker: RVMD returned +253.0% versus PBYI's -87.3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PBYI or RVMD?
By beta (market sensitivity over 5 years), Puma Biotechnology, Inc. (PBYI) is the lower-risk stock at 0.54β versus Revolution Medicines, Inc.'s 0.99β — meaning RVMD is approximately 83% more volatile than PBYI relative to the S&P 500. On balance sheet safety, Revolution Medicines, Inc. (RVMD) carries a lower debt/equity ratio of 10% versus 22% for Puma Biotechnology, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — PBYI or RVMD?
Puma Biotechnology, Inc. (PBYI) is the more profitable company, earning 13.6% net margin versus 0.0% for Revolution Medicines, Inc. — meaning it keeps 13.6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PBYI leads at 16.3% versus 0.0% for RVMD. At the gross margin level — before operating expenses — PBYI leads at 74.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — PBYI or RVMD?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is PBYI or RVMD better for a retirement portfolio?
For long-horizon retirement investors, Puma Biotechnology, Inc. (PBYI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.54)). Both have compounded well over 10 years (PBYI: -87.3%, RVMD: +253.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between PBYI and RVMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: PBYI is a small-cap deep-value stock; RVMD is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.